One subgroup of CRC that was identified in each subtyping study was the mesenchymal phenotype, characterized by worst clinical outcome, resistance to adjuvant chemotherapy, and elevated transforming growth factor-β (TGF-β) signaling, a well-established feature in the induction of epithelial-to-mesenchymal transition (EMT). Here, TGFB1 is linked to colorectal carcinoma.